Advanced search×

Alimentary Pharmacology and Therapeutics

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Ebscoatoz, CSA, Ovid from 2000, Ebsconet, Wiley from 1987, Ebsco, Gale, and Proquest

  1. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.

    Alimentary Pharmacology and Therapeutics 28(6):742 (2008) PMID 19145730

    Efficacy and safety of antiviral combination therapy in patients with Crohn's disease (CD) and chronic hepatitis C (CHC) is presently not established and consequently CHC is rarely treated in CD patients. To analyse the efficacy and tolerability of antiviral interferon/ribavirin therapy in patie...
  2. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease.

    Alimentary Pharmacology and Therapeutics 28(6):724 (2008) PMID 19145728

    The use of exclusive enteral nutrition to treat paediatric Crohn's disease (CD) is widely accepted, although the precise mechanism(s) of action remains speculative. To investigate the changes to key intestinal bacterial groups of Eubacteria, Bacteroides, Clostridium coccoides, Clostridium leptum...
  3. Clinical trial: oral feeding with a soft diet compared with clear liquid diet as initial meal in mild acute pancreatitis.

    Alimentary Pharmacology and Therapeutics 28(6):777 (2008) PMID 19145732

    In mild acute pancreatitis, traditional treatment has been initial fasting and oral refeeding with clear liquids to prevent adverse gastrointestinal events such as pain. The diet is gradually progressed to soft solids and hospital discharge is planned based on patients' tolerance to a solid diet...
  4. Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study.

    Alimentary Pharmacology and Therapeutics 28(6):789 (2008) PMID 19145734 PMCID PMC3717404

    Despite wide availability of physician guidelines for safer use of nonsteroidal anti-inflammatory drugs (NSAIDs) and widespread use of these drugs in the US, NSAID prescribing guidelines have been only modestly effective. To identify and describe comprehensively barriers to provider adherence to...
  5. Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods.

    Alimentary Pharmacology and Therapeutics 28(6):805 (2008) PMID 19145736 PMCID PMC2666354

    Tissue transglutaminase (TTG) antibodies and newly developed deamidated gliadin peptide (DGP) antibodies have better accuracy than native gliadin antibodies. Multiplex immunoassay (MIA) measures multiple antibodies simultaneously providing a complete antibody phenotype with reduced turnaround ti...
  6. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease.

    Alimentary Pharmacology and Therapeutics 28(6):749 (2008) PMID 18557988

    The thiopurines, azathioprine (AZA) and mercaptopurine are extensively used in Crohn's discase (CD). Thiopurine bioactivation can be diverted by either thiopurine methyltransferase (TPMT), or by xanthine oxidase/dehydrogenase (XOD) which forms 6-thiouric acid (6TU). To investigate whether chroni...
  7. Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury.

    Alimentary Pharmacology and Therapeutics 28(6):799 (2008) PMID 19145735

    A partially hydrolysed and dried product of pacific whiting fish is marketed as a health food supplement supporting 'intestinal health'. To examine whether the partially hydrolysed and dried product of pacific whiting fish influenced the small intestinal damaging side effects of the nonsteroidal...
  8. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.

    Alimentary Pharmacology and Therapeutics 28(6):663 (2008) PMID 18532992

    Many oral 5-aminosalicylic acid (5-ASA) formulations are designed to maximize 5-ASA release in the colon where it acts topically on the colonic mucosa. Delayed-release formulations and azo-prodrugs minimize 5-ASA absorption in the upper gastrointestinal (GI) tract. To review methods for assessin...
  9. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.

    Alimentary Pharmacology and Therapeutics 28(6):734 (2008) PMID 19145729

    Hepatotoxicity results in the withdrawal of thiopurines drugs, azathioprine (AZA) and mercaptopurine (MP), in up to 10% of patients with inflammatory bowel disease. Our group previously demonstrated that allopurinol with AZA/ciclosporin/steroid 'triple therapy' improved renal graft survival. To ...
  10. Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements.

    Alimentary Pharmacology and Therapeutics 28(6):689 (2008) PMID 19145725

    The evidence on whether antioxidant supplements prevent gastrointestinal cancers is contradictory. To assess the beneficial and harmful effects of antioxidant supplements in preventing gastrointestinal cancers. Using the Cochrane Collaboration methodology, we reviewed the randomized trials compa...